Biotech Values

[DewDiligence]

UMRX effectively reverse-merges into Kiq LLC:

https://www.prnewswire.com/news-releases/unum-therapeutics-inc-announces-acquisition-of-kiq-llc-301088435.html

Unum Therapeutics…today announced it has completed the acquisition of Kiq LLC ("Kiq"), a privately held, biotechnology company focused on the discovery and development of precision kinase inhibitors.

Concurrent with the acquisition of Kiq, Unum entered into a definitive agreement for the sale of Series A non-voting convertible Preferred Stock…in a private placement to a group of institutional accredited investors…to result in gross proceeds to Unum of approximately $104.4 million…

The proceeds from the private placement will be used to advance clinical testing of PLX9486, a highly potent and selective KIT D816V inhibitor, in multiple indications…

…On a pro forma basis and based upon the number of shares of Unum common stock and preferred stock issued in the acquisition and the concurrent financing, Unum equity holders immediately prior to the acquisition will own approximately 16.2% of Unum on a fully-diluted basis immediately after these transactions.